Authors: Kaudha E On behalf of the ODYSSEY trial Presented at: PEPFAR Uganda Science Summit Read
Search
resultsSearch
ResultsDolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV (combined results of the main trial and the ‘under 14kg’ cohort)
Authors: Anna Turkova on behalf of the ODYSSEY trial team Presented at: CHIVA 2021 (Oral presentation) Download
Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV(combined results of the main trial and the ‘under 14kg’ cohort)
Authors: Turkova A on behalf of the ODYSSEY trial team Presented at: CHIVA 2021 Read
Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the main ODYSSEY trial (≥14kg)
Authors: White E and Kityo C on behalf of the ODYSSEY trial team Presented at: CHIVA 2021 Read
Dolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV
Authors: Pauline Amuge on behalf of the ODYSSEY trial team Published in: International workshop on HIV pediatrics 2021 (Oral presentation) Download
A randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial
Authors: A Lugemwa, H Mujuru, B Wynne, A Violari, AR Kekitiinwa, CM Kity, M Archary, E Variava, T Sarfati, C Shakeshaft, R Turner, K Nathoo, E Chidziva, L Atwine, N Ramsagar, A Liberty, P Amuge, E Kaudha, A Nanduudu, R Mngqibisa, R Mosia, MF Cotton, TR Cressey, T...
Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
Authors: White E, Turkova A, Mujuru AH, Nankya I, Wynne B, Ali S, Kekitiinwa A, Lugemwa A, Kaudha E, Liberty A, Cassim H, Archary M, Cotton M, Barlow-Mosha L, Cressey RT, Ngampiyasakul C, Srirompotong U, Behuhuma O, Saidi Y, Bamford A, Kobbe R, Rojo P, Giaquinto C,...
Effect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial
Authors: L. Barlow-Mosha, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A. Mulindwa, G.A. Muzorah, D. Bbuye, M. Nolan, C. Giaquinto, D.M...
Effect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial
Authors: L. Barlow-Mosha, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A. Mulindwa, G.A. Muzorah, D. Bbuye, M. Nolan, C. Giaquinto, D.M...
No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial
Authors: T.G Jacobs, A. Colbers, H. Waalewijn, P. Amuge, D. Bbuye, E. Kaudha, A. Nanduudu, S. Makumbi, L. Atwine, S. Mudzingwa, K. Nathoo, J. Hakim, A. Liberty, A.J. Van Rensburg, M. Archary, D.M Gibb, D. Ford, A. Turkova, D.M Burger, ODYSSEY trial team Published in:...